Skip to main content
DRTS logo

Alpha Tau Medical Ltd.

DRTSNASDAQHealthcareBiotechnology

$12.29Today:- (-)1Y +250.93%

As of Oct 16, 2026 close

Market cap
$1.20B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$3.43$15.79
Volume (live)
-
Avg. volume (3M)
490.08K

Alpha Tau Medical (DRTS) Company Profile

Complete business overview, executive team, trading details, and corporate information.

Alpha Tau Medical Ltd.
DRTS•Nasdaq Stock Market•Healthcare•Biotechnology

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.

Company Information

CEOUzi Sofer
Founded2015
Employees121
CountryIsrael
Fiscal YearJanuary - December

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Phone972 3 577 4115
Address
Kiryat HaMada St. 5 Jerusalem, 9777605 Israel

Corporate Identifiers

CIK0001871321
CUSIPM0740A108
ISINIL0011839383
SIC3841

Leadership Team & Key Executives

Uzi Sofer
Chief Executive Officer and Chairman
Raphi Levy
Chief Financial Officer
Amnon Gat
Chief Operations Officer
Ronen Segal
Chief Technology Officer
Dr. Robert B. Den M.D.
Chief Medical Officer and Member of Scientific Advisory Board
Prof. Yona Keisari
Chief Scientific Officer and Member of Scientific Advisory board
Rebecca Becker
Vice President of legal
Yael Zeiger
Corporate Controller